Vertex Pharmaceuticals Inc
NASDAQ:VRTX

  • LAST PRICE
    471.8150
  • TODAY'S CHANGE (%)
    0.6950 (0.1475%)
  • Bid / Lots
    471.6400/ 1
  • Ask / Lots
    472.0000/ 6
  • Open / Previous Close
    473.9100 / 471.1200
  • Day Range
    468.7700
    475.4800
  • 52 Week Range
    341.9000
    510.6350
  • Volume
    807,901

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VRTX
Vertex Pharmaceuticals Inc
121.6B
-233.1x
+46.35%
REGN
Regeneron Pharmaceuticals Inc
93.0B
20.5x
+10.93%
BIIB
Biogen Inc
25.3B
15.7x
-18.14%
ICLR
ICON PLC
18.2B
24.3x
+4.68%
IQV
IQVIA Holdings Inc
38.1B
27.6x
+46.62%
MRNA
Moderna Inc
21.0B
-3.5x
---
As of 2024-11-04

Company Information

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Contact Information

Headquarters
50 Northern AvenueBOSTON, MA, United States 02210
Phone
617-341-6393
Fax
---

Executives

Executive Chairman of the Board
Jeffrey Leiden
President, Chief Executive Officer, Director
Reshma Kewalramani
Chief Financial Officer, Executive Vice President
Charles Wagner
Chief Operating Officer, Executive Vice President
Stuart Arbuckle
Executive Vice President - Global Research, Chief Scientific Officer
David Altshuler

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$121.6B
Revenue (TTM)
$10.3B
Shares Outstanding
258.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.38
EPS
$-2.02
Book Value
$68.22
P/E Ratio
-233.1x
Price/Sales (TTM)
11.8
Price/Cash Flow (TTM)
---
Operating Margin
-3.37%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.